Charles River Laboratories | CRL - Loan Capital

Stock Price
149.93
Daily Change
-0.92 -0.61%
Monthly
-19.19%
Yearly
6.05%
Q2 Forecast
147.82

Charles River Laboratories reported $2.66B in Loan Capital for its fiscal quarter ending in March of 2026.





Loan Capital Change Date
Agilent USD 3.05B 0 Dec/2025
Align Technology USD 0 0 Dec/2024
Bio-Rad Laboratories USD 802.9M 398.8M Mar/2026
Bruker USD 1.66B 189.6M Mar/2026
Cardinal Health USD 8.25B 102M Mar/2026
Charles River Laboratories USD 2.66B 526.77M Mar/2026
Cigna USD 29.37B 1.5B Mar/2026
Concord Medical Services Hldg CNY 2.27B 3.79M Jun/2025
CVS Health USD 60.53B 29M Mar/2026
Danaher USD 17.56B 855M Mar/2026
Dentsply International USD 2.01B 9M Mar/2026
Elevance Health USD 30.77B 29M Mar/2026
Humana USD 12.27B 95M Mar/2026
Illumina USD 1.49B 0 Mar/2026
Incyte USD 29.41M 785K Mar/2026
Intrexon USD 0 198.67M Jun/2024
IQVIA Holdings USD 13.99B 105M Mar/2026
Laboratory Of America USD 5.9B 748.3M Mar/2026
Lakefront Biotherapeutics EUR 4.85M 335K Mar/2026
Lonza CHF 3.88B 323M Dec/2025
McKesson USD 5.26B 166M Mar/2026
Merck EUR 10.8B 72M Mar/2026
Mettler Toledo International USD 2.16B 73.35M Mar/2026
Novartis USD 37.45B 7.86B Mar/2026
Pfizer USD 60.57B 1.08B Mar/2026
Quest Diagnostics USD 5.16B 12M Mar/2026
Revvity USD 2.63B 836K Mar/2026
Thermo Fisher Scientific USD 40.07B 4.22B Mar/2026
United Therapeutics USD 100M 100M Jun/2024
UnitedHealth USD 71.44B 880M Mar/2026
Veradigm USD 200.4M 69K Dec/2022
Waters USD 5.22B 3.81B Mar/2026
West Pharmaceutical Services USD 202.8M 0 Mar/2026